Edition:
India

Biomarin Pharmaceutical Inc (BMRN.OQ)

BMRN.OQ on NASDAQ Stock Exchange Global Select Market

85.02USD
19 Jun 2019
Change (% chg)

$-0.49 (-0.57%)
Prev Close
$85.51
Open
$85.39
Day's High
$86.40
Day's Low
$84.60
Volume
280,889
Avg. Vol
417,463
52-wk High
$106.69
52-wk Low
$79.15

About

BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products... (more)

Overall

Beta: 1.37
Market Cap(Mil.): $15,312.39
Shares Outstanding(Mil.): 179.07
Dividend: --
Yield (%): --

Financials

  BMRN.OQ Industry Sector
P/E (TTM): -- 32.51 37.25
EPS (TTM): -0.50 -- --
ROI: -2.31 12.52 12.15
ROE: -3.12 13.83 16.99

BioMarin says data shows hemophilia gene therapy effects could wane

BioMarin Pharmaceutical Inc said on Tuesday early trial data for its gene therapy for hemophilia A suggested the one-time infusion's effect on some patients' bleeding disorders would last eight years.

29 May 2019

Catalyst Pharma sees net price of drug, once free, topping $300,000

NEW YORK Catalyst Pharmaceuticals Inc said on Monday that it expects its drug for a rare disease, which had long been available to patients for free, will cost more than $300,000 per year including rebates to insurers and other discounts.

12 Feb 2019

Catalyst Pharma sees net price of drug, once free, topping $300,000

NEW YORK Catalyst Pharmaceuticals Inc said on Monday that it expects its drug for a rare disease, which had long been available to patients for free, will cost more than $300,000 per year including rebates to insurers and other discounts.

12 Feb 2019

Catalyst Pharma sees net price of drug, once free, topping $300,000

NEW YORK, Feb 11 Catalyst Pharmaceuticals Inc said on Monday that it expects its drug for a rare disease, which had long been available to patients for free, will cost more than $300,000 per year including rebates to insurers and other discounts.

12 Feb 2019

Earnings vs. Estimates